Brit Limited bounces back with $247.1 million profit

Brit Limited, part of the Fairfax group, enjoyed strong financial results in its 2021 on strong underwriting peformance.

The company reported a profit on ordinary activities before tax of $247.1 million against a pre-tax loss of $235.5 million in 2020.

Brit Limited further reported gross written premiums of $3,238.8 million against $2,424,2 million in 2020.

The company noted adjusted net tangible assets of $1,740.6 million against $1,436.8 million in 2020.

The firm also reported a capital surplus increase of 81.2% to $617.9 million against $341 million in 2020.

Fairfax owns 86.20% of Brit Limited.

“I am pleased to report a positive 2021 for Brit, with our underwriting performance and investment return delivering a strong overall result,” said interim group CEO Martin Thompson.

“Our clear strategy saw us deliver a combined ratio for the year of 95.7%. This reflected the combination of an excellent attritional ratio, prior year reserve releases and increased income from our third party capital management and MGA businesses.” 

“That we delivered this performance despite exposure to a number of major loss events and the continued impact of COVID-19 was particularly encouraging, demonstrating the increased resilience of our business and our firm focus on disciplined underwriting.”

“As well as delivering a good underwriting result, we grew our written premium by 31.8% to $3,238.3m.”

“This reflects strong, targeted growth in our core direct and reinsurance books, and a very successful first year of trading for Ki.”

Thompson added optimism for the company’s 2022 growth potential.

“Looking ahead to 2022, while uncertainty remains around COVID-19, rising inflation and the potential of increased frequency and severity of major loss events, we remain optimistic.” 

“Ongoing rate rises, continued improvement in our attritional claims ratio and our clear strategy give us confidence that Brit is well placed to respond to the opportunities and challenges ahead.”

CloudCoco shares reaches for the clouds with strong final results

0

CloudCoco shares soared 11.7% to 1.9p on Monday morning with strong results and a jump in EBITDA.

CloudCoco, the IT service and communications solutions company, saw an increase in EBITDA by 185% increasing from £261k in 2020 to £745km in 2021 as a byproduct of the acquisitions of Systems Assurance Limited and More Computers Limited.

Vantage Motor Group, Kings College London and boohoo signed renewed multiyear contracts during the group’s successful year. The contracts were billed in advanced, reflecting the growth of £130k in revenues to £8.1m in 2021. The liabilities also increased with renewed contracts to £1.3m in ’21 from £0.9m in ’20.

The pre-tax loss dropped from £2.9m in 2020 to £2m in 2021. However, to cater to profitability in the future the group has managed to raise £2.1m in fundraising for future acquisition prospects. With acquisitions, the firm expects to increase their services resulting in higher revenues and profitability.

Mark Halpin, Chief Executive Officer, CloudCoco said, “I’m delighted to report on another period of significant progress for CloudCoCo, with our platform now primed for sustainable, long-term growth.”

“FY21 was a landmark year for the Group and we are now a very different proposition in terms of scale and opportunity, which will be reflected in our FY22 financials. With an exceptional team in place, improving market conditions and having demonstrated our ability to overcome challenges as and when they arise, we remain confident in our ability to continue making good progress towards our growth ambitions.”

In Q1 post 2021 results, recurring managed services make up 72% of the sales in Q1 2022 which was only 41% in 2020.

IDE Group Connect and Nimoveri has been successfully acquired from IDE Group Holdings.

“Customer feedback remains exceptionally positive. We have a growing reputation for consistently delivering quality which, coupled with our enhanced service propositions, has allowed the Company to record its most successful sales quarter yet at the start of FY22,” stated Simon Duckworth, Chairman, CloudCoco.

New standard listing: More Acquisitions planned

More Acquisitions is a new cash shell focused on energy transition opportunities. There is no specific type of business that is being targeted but it should get the majority of its revenues from green products so that More Acquisitions can obtain the London Stock Exchange’s Green Economy Mark. A business with significant recurring revenues and international potential would be ideal.  
More Acquisitions has issued all shares at the same price and there was a cap on expenses. This means that the underlying NAV is 0.96p a share. The share price ended the first day at 1.15p (1p/1.3p). There w...

New standard listing: URA’s Zambia prospect

URA Holdings has returned to the London market after more than three years but this time it is the standard list and not AIM. The cash shell has secured the acquisition of Malaika Developments, which has exploration interests in eastern Zambia.
The directors will use their skills to exploit this opportunity and to seek others. The plan would be to develop and then sell them for equity, cash or royalties, or even agree a farm-out deal. The focus will be relatively stable countries in southern and central Africa. Management believes that there are opportunities in Zambia because other companies ...

Standard reversal: Alkemy Capital lithium project

Alkemy Capital Investments has been readmitted to the standard list after it set up a new subsidiary to potentially supply lithium hydroxide monohydrate to battery manufacturers. The new plant could be set up at Teesside in the freeport. The board is assessing the prospects for the project and a feasibility study should be delivered at the end of March.
There is an exclusivity agreement, so the board has time to decide whether the project is going to be commercial. If Alkemy Capital does decide to go ahead it will need to recruit a chief executive and raise more funding.
The shares were readmi...

AstraZeneca shares: is the pharma giant worth consideration?

AstraZeneca was a driving force behind tackling the Covid-19 pandemic with their vaccine roll-out, but is the company’s stock worth considering in 2022?

Despite enjoying a jump in revenue over the past year, AstraZeneca shares are up just 1% year to date.

The company reported strong financial results for 2021 with a revenue increase of 41% to $37,417 million.

AstraZeneca Dividend

AstraZeneca paid out a dividend of $2.87 per share for its 2021 financial year, which was well covered with a dividend cover of 1.9 and provides space for further dividend increases.

AstraZeneca currently has a 2.8% yield, broadly inline the FTSE 100 average.

The pharma producer saw an EPS of $0.08 for 2021, representing a dramatic 97% decrease compared to 2020.

“AstraZeneca continued on its strong growth trajectory in 2021, with industry-leading R&D productivity, five of our medicines crossing new blockbuster thresholds and the acquisition and integration of Alexion,” said AstraZeneca CEO Pascal Soriot.

“We also delivered on our promise of broad and equitable access to our Covid-19 vaccine with 2.5 billion doses released for supply around the world, and we made good progress on reducing our greenhouse gas emissions.”

“Growth was well balanced across our strategic areas of focus, and we saw double-digit growth in all major regions, including Emerging Markets despite some headwinds in China.”

AstraZeneca has also been engaged in deal making this year with a $760 million heart medicine agreement.

AstraZeneca Valuation

AstraZeneca’s historical PE Ratio is 22.5 which is forecast to fall to 17x earnings suggesting analysts are optimistic about the company’s outlook.

However, when compared to FTSE 100 peers GlaxoSmithKline and Hikma, Astra does appear expensive. GlaxoSmithKline and Hikma both have forward PE Ratios of 12.7.

This may pay testament to investor sentiment around AstraZeneca who are the best performing FTSE 100 Pharma so far in 2022 with shares up 1.1%. Glaxo shares are down 6.3%.

With Astra’s strong pipeline of drugs, and the strong sentiment around AstraZeneca leading to a premium when compared to peers, the AstraZeneca share price should be one to watch for an entry on further weakness.

FTSE 100 tumbles as fighting hits nuclear plant

FTSE 100 was trading down 2.6% at 7,050 following the news of Russia’s invasion lead to a fire in one of the largest Ukrainian nuclear power plants.

Oil prices continued to climb despite efforts to boost supply, but failed to lift shares in FTSE 100 oil companies with the market choosing to focus on the impact on household bills and further inflation.

“With the invasion of Ukraine by Russia now into its second week, stock markets continue to battle the threat of even higher inflation and a potential economic slowdown,” says Russ Mould, investment director at AJ Bell.

Tensions also rose as western powers mulled new sanctions on Russia which could potentially lead to an escalation if Russia chose to lash out in response.

“There will be more Russian banks taken out of the SWIFT system. I suspect all Russian-flagged ships will be banned from entering EU ports,” said Simon Coveney, Ireland’s foreign minister in an interview with RTE.

Putin has recently said “we do not see any need here to aggravate or worsen our relations. And all our actions, if they arise, they always arise exclusively in response to some unfriendly actions, actions against the Russian Federation.”

Broad FTSE 100 declines

International Consolidated Airlines shares have crashed 15% since Monday on concerns holiday makers will hold off from making bookings with a backdrop of war and rising prices.

ITV shares have continued their dip from yesterday and are trading down 6.5% to 74.9p after announcing their expansion plans for their streaming services. Despite a rise of 28% in revenues to £1.7bn, the investment of £180m into ITVX is not being taken well by investors.

HSBC shares were a major drag on the FTSE 100 after a 4.9% drop to 470.9p in Friday afternoon trade. Due to the exposure to global operations by HSBC, the bank is particularly exposed to geopolitical risk.

Marks & Spencer shares have seen a 2.7% dip on Friday after having to postpone shipments to FiBa group, M&S’ Turkish franchisee’s Russian business.

Hays’ shares have fallen 6.9% to 114.9p post the announcement of ceasing all business in Russia. The recruitment agency has chosen to shut their offices in Moscow and St Petersburg.

Coca-Cola HBC shares have been tanking all week and today, the shares were down 1.1% to 1,581p per share. The bottling company had to halt production in their Kiev plant as a result of the invasion. Emerging markets are CCHBC’s largest contributors to their revenues, and with the production pause, serious consequences are expected to be seen in their next earnings update.

Evraz volatility

Evraz shares soared 49.2% to 80.1p as investors jumped on the rollercoaster that is FTSE 100 shares with exposure to Russia. However, with the conflict in Ukraine accelerating rapidly, the company’s future remains uncertain and the shares look set for a continued volatility.

Polymetal saw its stock climb to 25.8% to 223p due to similar circumstances as bargain-hunters swooped in to purchase the stock after its lost 80% of its value in 2022.

Fresnillo saw a rise of 6.3% to 726.7p due to increasing gold and commodities prices, with interest accumulating in safe haven investments such as gold as market volatility spikes.

Oncimmune contracted to profile autoantibody of CIDP

0

Oncimmune has been contracted by a global pharmaceutical leader to study autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Oncimmune, the immunodiagnostics company, is using their ImmunoINSIGHTS autoantibody profiling service to understand autoimmune illness and infectious diseases.

SeroTag Infectious Diseases discovery array allows scientists to better understand how SARS-CoV-2 triggers an immune response and forecast how vaccines and treatments for the virus will work using the group’s proprietary biomarker discovery platform.

CIDP is an autoimmune illness that targets the myelin sheaths, which are the fatty coatings that insulate and protect nerves. In its acute phase, CIDP is commonly referred to as Guillain-Barré syndrome, but it is chronic, difficult to diagnose, and can result in irreversible physical damage if not treated early on.

For the new contract, Oncimmune will use SertoTag to discover autoantibodies with a connection to CIDP. Using ImmunoINSIGHTS, the firm can manufacture specific antigens associated with CIDP via the group’s SeroTag platform. SeroTag will screen tests from patients with CIDP to find autoantibodies with relevance.

Dr. Adam M Hill, Chief Executive Officer, Oncimmune commented,”We are pleased to announce this contract with another leading pharmaceutical company, adding to the growing list of global partners, working with us in the rare disease space where there is a real clinical need and opportunity to make a significant impact.”

“This contract will make full use of the unique attributes of our SeroTag platform, and the competencies amongst our scientific colleagues, who are world leaders in autoimmune profiling.”

“As is typical with SeroTag contracts, there is potential for the initial discovery work in autoantibodies to progress to further research and support for therapeutic development, creating and refining CIPD-specific NavigAID panels using additional data and markers to guide drug development and inform patient and disease stratification.”

Morgan Advanced Materials post 43.2% earnings jump

Morgan Advanced Materials enjoyed an 8.7% of its share price to 312p in early morning Friday trading upon the release of strong 2021 financial results.

The materials company reported a 4.4% increase in revenue, up to £950.5 million from £910.7 million in 2020.

Moran Advanced Materials posted an adjusted operating profit increase of 35.8% to £124.5 million compared to £91.7 million in 2020.

The Group further reported an adjusted earnings-per-share increase of 43.2% to 27.2p.

Morgan Advanced Materials announced that it expects a revenue growth of 4-7% over 2022.

The company is also scheduled to increase its exposure to faster growing sectors including clean energy, semiconductors, clean transportation and healthcare.

The Group added that it had severed all its ties to Russia, which accounted for less than 0.5% (£4 million) of all company revenues.

“2021 was the second challenging year with the COVID-19 pandemic driving various restrictions on mobility and activity around the world,” said Morgan Advanced Materials CEO Pete Raby.

“Demand recovered strongly across the global economy following the sharp slowdown in 2020, and the combination of high demand and the pandemic led to supply chain disruptions and inflation in materials and labour in various parts of our business.”

“Nevertheless, in spite of these challenges, we have made good progress as a business, with further implementation of our strategy and progress against our long-term goals.”

“This resulted in strong growth and saw margins at their highest point in more than 20 years.”

The strong results gave the board the confidence to hike the dividend to 9.1p which is well cover by adjusted EPS 27.2p.

Gore Street completes first continental Europe acquisition

0

Gore Street Energy Storage Fund announced the completed acquisition of a 28 MWh operational energy storage asset in Cremzow, Germany.

The Fund saw its share price dip 0.3% to 117.1p on Friday during early morning trading.

Gore Street announced that it had acquired a 90% stake in the asset, with German renewable developer Enertrag maintaining a 10% stake and supporting technical management of the venture.

The company reported that the acquisition would bring its operating assets 232 MW alongside total portfolio assets under management to 629 MW.

The announcement was in line with Gore Street’s mandate to expand outside the UK and Ireland.

The move reportedly allows the company to expand into Europe and participate in wholesale and intra-day arbitrage as a means to bring additional revenue stacking opportunities to the Fund.

Gore Street confirmed that the system is based LG Chem lithium-ion batteries.

“This is a landmark acquisition with compelling fundamentals which not only demonstrates our entry into new markets but also increases our operational cash generating assets, and further diversifies Gore Street’s portfolio,” said Gore Street CEO Alex O’Cinneide.

“We are very pleased to have worked with ENEL on this transaction and look forward to continuing to partner with Enertrag to optimise the asset going forwards.”

“Energy storage is an ever-increasing infrastructure requirement, and we will continue to seek out the best opportunities from our considerable pipeline across our key markets.”